"Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!"
written by Udaya M. Kabadi,
published by Journal of Diabetes Mellitus, Vol.6 No.2, 2016
has been cited by the following article(s):
  • Google Scholar
  • CrossRef
[1] CARDIOVASCULAR OUTCOME TRIALS IN TYPE 2 DIABETES: RELIABLE OR BIASED!
WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH, 2017